

Emily Reeve

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3068585/publications.pdf>

Version: 2024-02-01

98
papers

5,263
citations

136940

32
h-index

88628

70
g-index

103
all docs

103
docs citations

103
times ranked

3462
citing authors

#	ARTICLE	IF	CITATIONS
1	Reducing Inappropriate Polypharmacy. <i>JAMA Internal Medicine</i> , 2015, 175, 827.	5.1	1,054
2	A systematic review of the emerging definition of "deprescribing"™ with network analysis: implications for future research and clinical practice.. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1254-1268.	2.4	461
3	Patient Barriers to and Enablers of Deprescribing: a Systematic Review. <i>Drugs and Aging</i> , 2013, 30, 793-807.	2.7	364
4	Review of deprescribing processes and development of an evidence-based, patient-centred deprescribing process. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 738-747.	2.4	246
5	Deprescribing: A narrative review of the evidence and practical recommendations for recognizing opportunities and taking action. <i>European Journal of Internal Medicine</i> , 2017, 38, 3-11.	2.2	204
6	People's Attitudes, Beliefs, and Experiences Regarding Polypharmacy and Willingness to Deprescribe. <i>Journal of the American Geriatrics Society</i> , 2013, 61, 1508-1514.	2.6	182
7	Assessment of Attitudes Toward Deprescribing in Older Medicare Beneficiaries in the United States. <i>JAMA Internal Medicine</i> , 2018, 178, 1673.	5.1	142
8	Development and Validation of the Revised Patients'™ Attitudes Towards Deprescribing (rPATD) Questionnaire: Versions for Older Adults and Caregivers. <i>Drugs and Aging</i> , 2016, 33, 913-928.	2.7	131
9	Beliefs and attitudes of older adults and carers about deprescribing of medications: a qualitative focus group study. <i>British Journal of General Practice</i> , 2016, 66, e552-e560.	1.4	117
10	A systematic review of interventions to deprescribe benzodiazepines and other hypnotics among older people. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 927-935.	1.9	114
11	Alterations in drug disposition in older adults. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 491-508.	3.3	91
12	Barriers to Optimising Prescribing and Deprescribing in Older Adults with Dementia: A Narrative Review. <i>Current Clinical Pharmacology</i> , 2015, 10, 168-177.	0.6	89
13	Older peoples'™ attitudes regarding polypharmacy, statin use and willingness to have statins deprescribed in Australia. <i>International Journal of Clinical Pharmacy</i> , 2015, 37, 949-957.	2.1	86
14	Development and validation of the patients'™ attitudes towards deprescribing (PATD) questionnaire. <i>International Journal of Clinical Pharmacy</i> , 2013, 35, 51-56.	2.1	85
15	Benefits of deprescribing on patients'™ adherence to medications. <i>International Journal of Clinical Pharmacy</i> , 2014, 36, 26-29.	2.1	77
16	Health Care Practitioners'™ Perspectives on Deprescribing Anticholinergic and Sedative Medications in Older Adults. <i>Annals of Pharmacotherapy</i> , 2016, 50, 625-636.	1.9	76
17	Attitudes towards polypharmacy and medication withdrawal among older inpatients in Italy. <i>International Journal of Clinical Pharmacy</i> , 2016, 38, 454-461.	2.1	73
18	The benefits and harms of deprescribing. <i>Medical Journal of Australia</i> , 2014, 201, 386-389.	1.7	72

#	ARTICLE	IF	CITATIONS
19	Attitudes of Older Adults and Caregivers in Australia toward Deprescribing. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 1204-1210.	2.6	70
20	Are residents of aged care facilities willing to have their medications deprescribed?. <i>Research in Social and Administrative Pharmacy</i> , 2016, 12, 784-788.	3.0	67
21	Feasibility of a Patient-Centered Deprescribing Process to Reduce Inappropriate Use of Proton Pump Inhibitors. <i>Annals of Pharmacotherapy</i> , 2015, 49, 29-38.	1.9	65
22	Community-dwelling older people's attitudes towards deprescribing in Canada. <i>Research in Social and Administrative Pharmacy</i> , 2017, 13, 864-870.	3.0	63
23	Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary. <i>Medical Journal of Australia</i> , 2019, 210, 174-179.	1.7	61
24	Deprescribing tools: a review of the types of tools available to aid deprescribing in clinical practice. <i>Journal of Pharmacy Practice and Research</i> , 2020, 50, 98-107.	0.8	61
25	A systems approach to identifying the challenges of implementing deprescribing in older adults across different health-care settings and countries: a narrative review. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 233-245.	3.1	58
26	Pharmacokinetic and pharmacodynamic alterations in older people with dementia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 651-668.	3.3	55
27	Deprescribing: Future directions for research. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 801-805.	3.0	54
28	A narrative review of the safety concerns of deprescribing in older adults and strategies to mitigate potential harms. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 39-49.	2.4	48
29	Consumer Attitudes Towards Deprescribing: A Systematic Review and Meta-Analysis. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2022, 77, 1020-1034.	3.6	45
30	What do older adults with multimorbidity and polypharmacy think about deprescribing? The LESS study - a primary care-based survey. <i>BMC Geriatrics</i> , 2020, 20, 435.	2.7	44
31	Analgesic use, pain and daytime sedation in people with and without dementia in aged care facilities: a cross-sectional, multisite, epidemiological study protocol. <i>BMJ Open</i> , 2014, 4, e005757-e005757.	1.9	34
32	The Ethics of Deprescribing in Older Adults. <i>Journal of Bioethical Inquiry</i> , 2016, 13, 581-590.	1.5	34
33	Alterations in drug disposition in older adults: a focus on geriatric syndromes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 41-52.	3.3	33
34	Deprescribing Education vs Usual Care for Patients With Cognitive Impairment and Primary Care Clinicians. <i>JAMA Internal Medicine</i> , 2022, 182, 534.	5.1	33
35	Development and pilot testing of the revised Patientsâ€™ Attitudes Towards Deprescribing questionnaire for people with cognitive impairment. <i>Australasian Journal on Ageing</i> , 2018, 37, E150-E154.	0.9	32
36	Potentially inappropriate medication and attitudes of older adults towards deprescribing. <i>PLoS ONE</i> , 2020, 15, e0240463.	2.5	32

#	ARTICLE	IF	CITATIONS
37	Withdrawal of antihypertensive drugs in older people. The Cochrane Library, 2020, 2020, CD012572.	2.8	31
38	Deprescribing interventions in primary health care mapped to the Behaviour Change Wheel: A scoping review. Research in Social and Administrative Pharmacy, 2021, 17, 1229-1241.	3.0	28
39	Prevalence of statin-drug interactions in older people: a systematic review. European Journal of Clinical Pharmacology, 2016, 72, 513-521.	1.9	27
40	Impact of the Goal-directed Medication Review Electronic Decision Support System on Drug Burden Index: A cluster-randomised clinical trial in primary care. British Journal of Clinical Pharmacology, 2021, 87, 1499-1511.	2.4	26
41	Prevalence of Potential and Clinically Relevant Statin-Drug Interactions in Frail and Robust Older Inpatients. Drugs and Aging, 2015, 32, 849-856.	2.7	25
42	How general practitioners would deprescribe in frail oldest-old with polypharmacy – the LESS study. BMC Family Practice, 2018, 19, 169.	2.9	24
43	Clinicians' Perspectives on Barriers and Enablers of Optimal Prescribing in Patients with Dementia and Coexisting Conditions. Journal of the American Board of Family Medicine, 2019, 32, 383-391.	1.5	24
44	Leveraging implementation science to increase the translation of deprescribing evidence into practice. Research in Social and Administrative Pharmacy, 2022, 18, 2550-2555.	3.0	22
45	Designing a Primary Care-Based Deprescribing Intervention for Patients with Dementia and Multiple Chronic Conditions: a Qualitative Study. Journal of General Internal Medicine, 2020, 35, 3556-3563.	2.6	21
46	Medicine information exchange networks among healthcare professionals and prescribing in geriatric medicine wards. British Journal of Clinical Pharmacology, 2017, 83, 1185-1196.	2.4	20
47	The OPTIMIZE patient- and family-centered, primary care-based deprescribing intervention for older adults with dementia or mild cognitive impairment and multiple chronic conditions: study protocol for a pragmatic cluster randomized controlled trial. Trials, 2020, 21, 542.	1.6	20
48	COVID-19 Pandemic: Considerations for Safe Medication Use in Older Adults with Multimorbidity and Polypharmacy. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 1068-1073.	3.6	20
49	General practitioners' deprescribing decisions in older adults with polypharmacy: a case vignette study in 31 countries. BMC Geriatrics, 2021, 21, 19.	2.7	20
50	Enhancing Continuing Education Activities Using Audience Response Systems: A Single-Blind Controlled Trial. Journal of Continuing Education in the Health Professions, 2015, 35, 38-45.	1.3	19
51	Enhancing Education Activities for Health Care Trainees and Professionals Using Audience Response Systems. Journal of Continuing Education in the Health Professions, 2015, 35, 261-269.	1.3	18
52	Clinical practice guidelines for older people with multimorbidity and life-limiting illness: what are the implications for deprescribing?. Therapeutic Advances in Drug Safety, 2018, 9, 619-630.	2.4	18
53	The Impact of Pharmacist Interventions on Quality Use of Medicines, Quality of Life, and Health Outcomes in People with Dementia and/or Cognitive Impairment: A Systematic Review. Journal of Alzheimer's Disease, 2019, 71, 83-96.	2.6	18
54	The impact of in hospital patient-education intervention on older people's attitudes and intention to have their benzodiazepines deprescribed: a feasibility study. Therapeutic Advances in Drug Safety, 2019, 10, 204209861881656.	2.4	18

#	ARTICLE	IF	CITATIONS
55	Patientsâ€™ and Caregiversâ€™ Attitudes Toward Deprescribing in Singapore. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 1053-1060.	3.6	18
56	Cross-cultural adaptation and psychometric validation of the revised Patientsâ€™ Attitudes Towards Deprescribing (rPATD) questionnaire in French. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 1453-1462.	3.0	17
57	Deprescribing: Moving beyond barriers and facilitators. <i>Research in Social and Administrative Pharmacy</i> , 2022, 18, 2547-2549.	3.0	17
58	Implementation of the Goal-directed Medication review Electronic Decision Support System (G-MEDSS)Â© into home medicines review: a protocol for a cluster-randomised clinical trial in older adults. <i>BMC Geriatrics</i> , 2020, 20, 51.	2.7	15
59	Barriers and enablers of older adults initiating a deprescribing conversation. <i>Patient Education and Counseling</i> , 2022, 105, 615-624.	2.2	15
60	â€œOptimising Pharmacotherapy In the multimorbid elderly in primary Careâ€™ (OPTICA) to improve medication appropriateness: study protocol of a cluster randomised controlled trial. <i>BMJ Open</i> , 2019, 9, e031080.	1.9	13
61	Deprescribing: What do we know, and where to next?. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 722-724.	2.4	13
62	Exploration of verbal repetition in people with dementia using an online symptom-tracking tool. <i>International Psychogeriatrics</i> , 2017, 29, 959-966.	1.0	12
63	Influencers on deprescribing practice of primary healthcare providers in Nova Scotia: An examination using behavior change frameworks. <i>Medicine Access Point of Care</i> , 2020, 4, 239920262092250.	1.0	12
64	Attitudes toward deprescribing in a middle-aged health disparities population. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1502-1507.	3.0	12
65	The utility of a computerised clinical decision support system intervention in home medicines review: A mixed-methods process evaluation. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 715-722.	3.0	12
66	Baseline characteristics and comparability of older multimorbid patients with polypharmacy and general practitioners participating in a randomized controlled primary care trial. <i>BMC Family Practice</i> , 2021, 22, 123.	2.9	12
67	Views of medical practitioners about deprescribing in older adults: Findings from an Italian qualitative study. <i>Maturitas</i> , 2020, 134, 29-33.	2.4	11
68	Using the behavior change wheel to link published deprescribing strategies to identified local primary healthcare needs. <i>Research in Social and Administrative Pharmacy</i> , 2022, 18, 3350-3357.	3.0	11
69	Attitudes to Drug Use in Residential Aged Care Facilities: A Cross-Sectional Survey of Nurses and Care Staff. <i>Drugs and Aging</i> , 2021, 38, 697-711.	2.7	10
70	Development, validation and evaluation of the Goal-directed Medication review Electronic Decision Support System (G-MEDSS)Â©. <i>Research in Social and Administrative Pharmacy</i> , 2022, 18, 3174-3183.	3.0	10
71	Clinician agreement and influence of medication-related characteristics on assessment of polypharmacy. <i>Pharmacology Research and Perspectives</i> , 2017, 5, e00321.	2.4	9
72	Pharmacoepidemiology in older people: Purposes and future directions. <i>Therapie</i> , 2019, 74, 325-332.	1.0	9

#	ARTICLE	IF	CITATIONS
73	Patients' perspectives on the brave new word "deprescribing". International Journal of Pharmacy Practice, 2015, 23, 90-91.	0.6	7
74	Development and dissemination of the national strategic action plan for reducing inappropriate polypharmacy in older Australians. Internal Medicine Journal, 2021, 51, 111-115.	0.8	7
75	Can existing tools predict older adults' willingness to deprescribe? Considerations for D-PRESCRIBE's post-hoc secondary analysis. Research in Social and Administrative Pharmacy, 2019, 15, 1379-1380.	3.0	6
76	Pharmacist-led intervention to improve medication use in older inpatients using the Drug Burden Index: a study protocol for a before/after intervention with a retrospective control group and multiple case analysis. BMJ Open, 2020, 10, e035656.	1.9	5
77	Deprescribing Guidelines: Value of an Interactive Mobile Application. PRiMER (Leawood, Kan), 2020, 4, 26.	0.6	5
78	Difficulties Reducing Inappropriate Prescribing of Proton Pump Inhibitors in the Elderly. Drugs and Aging, 2012, 29, 925-926.	2.7	4
79	Considerations for systematic reviews of quantitative surveys: Learnings from a systematic review of the Patients' Attitudes Towards Deprescribing questionnaire. Research in Social and Administrative Pharmacy, 2022, 18, 2345-2349.	3.0	4
80	The role of the OncPal deprescribing guideline in end-of-life care. Supportive Care in Cancer, 2015, 23, 899-899.	2.2	3
81	Withdrawal of antihypertensive drugs in older people. The Cochrane Library, 0, , .	2.8	3
82	Hospital pharmacists' beliefs about optimising statin therapy in older inpatients. Journal of Pharmacy Practice and Research, 2017, 47, 223-227.	0.8	3
83	Development and validation of a tool to understand health care professionals' attitudes towards deprescribing (HATD) in older adults with limited life expectancy. Research in Social and Administrative Pharmacy, 2022, 18, 3596-3601.	3.0	3
84	Perspectives on Deprescribing Communication in Primary Care. Journal of General Internal Medicine, 2021, 36, 1122-1122.	2.6	2
85	Incorporating research into current pharmacy practice: the future of Australian pharmacy?. Journal of Pharmacy Practice and Research, 2016, 46, 397-398.	0.8	1
86	Tapering or abrupt cessation of proton pump inhibitors?. European Journal of Clinical Pharmacology, 2017, 73, 923-924.	1.9	1
87	Reply to: Deprescribing Attitudes of Older Adults Receiving Medication Management Support from Home-Based Nurses. Journal of the American Geriatrics Society, 2019, 67, 1757-1758.	2.6	1
88	P340: CLINICIANS' PERSPECTIVES ON BARRIERS AND ENABLERS TO OPTIMIZING PRESCRIBING IN PEOPLE WITH DEMENTIA AND COEXISTING CONDITIONS. Alzheimer's and Dementia, 2018, 14, P1329.	0.8	0
89	Are general practitioners willing to deprescribe in oldest-old patients with polypharmacy?. European Journal of Public Health, 2019, 29, .	0.3	0
90	Medication-related criteria in frailty assessment tools: A narrative review. Australasian Journal on Ageing, 2020, 39, e460-e465.	0.9	0

#	ARTICLE	IF	CITATIONS
91	Consideration of frailty versus limited life expectancy when deprescribing. Journal of Pharmacy Practice and Research, 2021, 51, 185-186.	0.8	0
92	Polypharmacy and Frailty. , 2021, , 3877-3880.		0
93	Potentially inappropriate medication and attitudes of older adults towards deprescribing. , 2020, 15, e0240463.		0
94	Potentially inappropriate medication and attitudes of older adults towards deprescribing. , 2020, 15, e0240463.		0
95	Potentially inappropriate medication and attitudes of older adults towards deprescribing. , 2020, 15, e0240463.		0
96	Potentially inappropriate medication and attitudes of older adults towards deprescribing. , 2020, 15, e0240463.		0
97	Potentially inappropriate medication and attitudes of older adults towards deprescribing. , 2020, 15, e0240463.		0
98	Potentially inappropriate medication and attitudes of older adults towards deprescribing. , 2020, 15, e0240463.		0